BMO Capital Downgrades Stealth BioTherapeutics (MITO) to Market Perform
Tweet
Share
E-mailGet Alerts MITO Hot Sheet
Price: $0.32 --0%
Rating Summary:
5 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 19 | New: 5
Rating Summary:
5 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 19 | New: 5
Join SI Premium – FREE
BMO Capital analyst Matthew Luchini downgraded Stealth BioTherapeutics (NASDAQ: MITO) from Outperform to Market Perform with a price target of $7.00 (from $28.00).
For an analyst ratings summary and ratings history on Stealth BioTherapeutics click here. For more ratings news on Stealth BioTherapeutics click here.
Shares of Stealth BioTherapeutics closed at $13.70 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Downgrades International Paper (IP) to Neutral
- JPMorgan Downgrades Guangzhou Automobile Group (2238:HK) (GNZUF) to Underweight
- Merck (MRK) PT Raised to $142 at BMO Capital
Create E-mail Alert Related Categories
DowngradesRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
